荧光素二(beta-D-吡喃半乳糖苷) | 17817-20-8

• 物质功能分类: 生物化工 - 糖类化合物 - 单糖
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 荧光素二(beta-D-吡喃半乳糖苷)
• 中文别名: 荧光素二(β-D-吡喃半乳糖苷)；荧光素二(BETA-D-吡喃半乳糖苷)
• 英文名称: fluorescein di-β-D-galactopyranoside
• 英文别名: Fluorescein-digalactoside；3',6'-bis[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]spiro[2-benzofuran-3,9'-xanthene]-1-one
• CAS: 17817-20-8
• 化学式: C₃₂H₃₂O₁₅
• mdl: MFCD00077344
• 分子量: 656.597
• InChiKey: ZTOBILYWTYHOJB-WBCGDKOGSA-N

物化性质

• 熔点：
  200-203 °C (dec.)
• 沸点：
  974.8±65.0 °C(Predicted)
• 密度：
  1.74±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  47
• 可旋转键数：
  6
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.406
• 拓扑面积：
  234
• 氢给体数：
  8
• 氢受体数：
  15

安全信息

• WGK Germany：
  3
• 海关编码：
  32129000
• 安全说明：
  S22,S24/25

制备方法与用途

生物活性

荧光素二（β-D-半乳糖吡喃苷）是 β-半乳糖苷酶的荧光底物，其激发波长为 485 nm，发射波长为 535 nm。

体外研究

荧光素二（β-D-半乳糖吡喃苷）产生的荧光在时间和剂量方面均呈依赖性增加。采用双底物方法所产生的荧光水平远低于使用荧光素二（β-D-半乳糖吡喃苷）的方法。结果显示，Hs68 细胞中由荧光素二（β-D-半乳糖吡喃苷）产生的荧光与传代次数成正比。

文献信息

• [EN] SITE-SPECIFIC RADIOFLUORINATION OF PEPTIDES WITH 8-[18F]-FLUOROOCTANOIC ACID CATALYZED BY LIPOIC ACID LIGASE<br/>[FR] RADIOFLUORATION SPÉCIFIQUE DE SITE DE PEPTIDES AVEC DE L'ACIDE 8-[18F]FLUOROOCTANOÏQUE CATALYSÉE PAR UNE ACIDE LIPOÏQUE LIGASE
  申请人：UNIV CALIFORNIA

  公开号：WO2017095806A1

  公开（公告）日：2017-06-08

  New methodologies for site-specifically radiolabeling proteins with the PET isotope [18F] are required to generate high quality radiotracers for imaging in both the preclinical and clinical settings. The enzymatic radiofluorination overcomes many of the limitations encountered to date with purely chemical approaches. The bacterial enzyme lipoic acid ligase was used to conjugate [18F]-fluorooctanoic acid to both a small peptide and a Fab antibody fragment. Labeling was site-specific and highly efficient under mild aqueous conditions using small amounts of peptide/protein (1-10 nmol). The labeled construct retained full epitope binding affinity and was stable in mouse serum. Using an optimized reaction scheme, mCi quantities of [18F]-Fab were generated, an amount sufficient for human imaging.

  用PET同位素[18F]对蛋白质进行特异性标记的新方法对于在临床前和临床环境中生成高质量放射示踪剂是必需的。酶促放氟反应克服了迄今为止纯化学方法所遇到的许多限制。细菌酶硫辛酸连接酶被用于将[18F]-氟辛酸与小肽和Fab抗体片段结合。在温和水性条件下，使用少量的肽/蛋白质（1-10 nmol），标记是特异性的且高效的。标记的构建物保留了完整的抗原结合亲和力，并在小鼠血清中稳定。使用优化的反应方案，产生了足够进行人体成像的mCi数量的[18F]-Fab。
• Saccharide Fluorescent Substrates, Preparation Method and Uses Thereof
  申请人：Texier-Nogues Isabelle

  公开号：US20080299044A1

  公开（公告）日：2008-12-04

  The invention concerns saccharide type fluorescent enzymatic substrates comprising on the same saccharide unit a fluorophor F1 and an inhibitor of the fluorescence of F1, and their use for preparing a diagnostic reagent for in vivo functional imaging, as well as a diagnostic reagent containing at least such an enzymatic substrate.

  这项发明涉及糖类荧光酶底物，其在同一糖类单元上包含荧光色团F1和F1荧光抑制剂，并且它们用于制备用于体内功能成像的诊断试剂，以及含有至少这种酶底物的诊断试剂。
• [EN] INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF<br/>[FR] INHIBITEURS D'AGRÉGATS D'ARN ASSOCIÉS À LA RÉPÉTITION DE POLYNUCLÉOTIDES ET LEURS UTILISATIONS
  申请人：VALORISATION RECH

  公开号：WO2015042685A1

  公开（公告）日：2015-04-02

  Compounds which inhibit the formation and/or accumulation of RNA foci, such as those due to polynucleotide repeats (e.g., trinucleotide repeats) are described herein. Also described herein are uses of such compounds, such as for the inhibition of the formation and accumulation such RNA foci, as well as for the treatment of polynucleotide repeat disorders (e.g., trinucleotide repeat disorders), such as myotonic dystrophy (e.g., DM1). Such compounds include compounds of formula 1, 1a, 1b, 2, 2a and (3) described herein.

  本文描述了抑制RNA斑点的形成和/或积累的化合物，例如由于多核苷酸重复（例如三核苷酸重复）而产生的斑点。本文还描述了这些化合物的用途，例如用于抑制这种RNA斑点的形成和积累，以及用于治疗多核苷酸重复疾病（例如三核苷酸重复疾病），如肌萎缩性肌无力（例如DM1）。这些化合物包括本文描述的1、1a、1b、2、2a和（3）式的化合物。
• Methods and compositions for protein labeling using lipoic acid ligases
  申请人：Ting Alice Y.

  公开号：US20090149631A1

  公开（公告）日：2009-06-11

  The invention provides compositions and methods of use thereof for labeling peptide and proteins in vitro or in vivo. The methods described herein employ lipoic acid ligase or mutants thereof, and lipoic acid analogs recognized by lipoic acid ligase and lipoic acid ligase mutants.

  本发明提供了一种用于体外或体内标记多肽和蛋白质的组合物及其使用方法。所述方法采用硫辛酸连接酶或其突变体，以及被硫辛酸连接酶和硫辛酸连接酶突变体所识别的硫辛酸类似物。
• Guanidinoglycoside-mediated liposome-based delivery of therapeutics
  申请人：The Regents of the University of California

  公开号：US20180086782A1

  公开（公告）日：2018-03-29

  This disclosure relates to the incorporation of amphiphilic guanidinylated aminoglycosides (e.g., neomycin) into liposomal assemblies, which contain entrapped therapeutics. The lysosome is responsible for enzymatically breaking down and recycling large biomolecules and aged organelles. While malfunctioned lysosomal enzymes have been established in Lysosomal Storage Disorders (LSDs), recent reports have suggested that defects in lysosomal enzymes (e.g., glucocerebrosidase) are also linked to other chronic ailments, including neurological disorders such as Parkinson's Disease and related disorders.

  本公开涉及将两性亲和性胍基化氨基糖苷（例如新霉素）纳入含有封闭治疗剂的脂质体聚集体中。溶酶体负责酶解和回收大分子生物分子和老化的细胞器。虽然已经确定溶酶体酶在溶酶体贮积病（LSDs）中存在故障，但最近的报告表明，溶酶体酶（例如葡萄糖鞘脂酶）的缺陷也与其他慢性疾病有关，包括神经疾病如帕金森病及相关疾病。